PMID- 21234380
OWN - NLM
STAT- MEDLINE
DCOM- 20110421
LR  - 20231105
IS  - 1740-2530 (Electronic)
IS  - 1740-2522 (Print)
IS  - 1740-2522 (Linking)
VI  - 2011
DP  - 2011
TI  - Timing of antiretroviral therapy for HIV in the setting of TB treatment.
PG  - 103917
LID - 10.1155/2011/103917 [doi]
LID - 103917
AB  - The convergent human immunodeficiency virus (HIV) and tuberculosis (TB) pandemics 
      continue to collectively exact significant morbidity and mortality worldwide. 
      Highly active antiretroviral therapy (HAART) has been a critical component in 
      combating the scourge of these two conditions as both a preemptive and 
      therapeutic modality. However, concomitant administration of antiretroviral and 
      antituberculous therapies poses significant challenges, including cumulative drug 
      toxicities, drug-drug interactions, high pill burden, and the immune 
      reconstitution inflammatory syndrome (IRIS), thus complicating the management of 
      coinfected individuals. This paper will review data from recent studies regarding 
      the optimal timing of HAART initiation relative to TB treatment, with the 
      ultimate goal of improving coinfection-related morbidity and mortality while 
      mitigating toxicity resulting from concurrent treatment of both infections.
FAU - Piggott, Damani A
AU  - Piggott DA
AD  - Division of Infectious Diseases, Department of Medicine, Johns Hopkins University 
      School of Medicine, 1550 Orleans Street, Rm 110, Baltimore, MD 21231, USA.
FAU - Karakousis, Petros C
AU  - Karakousis PC
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20101227
PL  - Egypt
TA  - Clin Dev Immunol
JT  - Clinical & developmental immunology
JID - 101183692
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - AIDS-Related Opportunistic Infections/complications/drug therapy
MH  - Anti-HIV Agents/*administration & dosage/*pharmacokinetics/therapeutic use
MH  - *Antiretroviral Therapy, Highly Active
MH  - Antitubercular Agents/*administration & dosage/*pharmacokinetics/therapeutic use
MH  - Clinical Trials as Topic
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - HIV Infections/*complications/*drug therapy/virology
MH  - HIV-1/drug effects
MH  - Humans
MH  - Mycobacterium tuberculosis/drug effects
MH  - Treatment Outcome
MH  - Tuberculosis/*complications/*drug therapy
PMC - PMC3017895
EDAT- 2011/01/15 06:00
MHDA- 2011/04/22 06:00
PMCR- 2010/12/27
CRDT- 2011/01/15 06:00
PHST- 2010/07/27 00:00 [received]
PHST- 2010/10/06 00:00 [revised]
PHST- 2010/10/20 00:00 [accepted]
PHST- 2011/01/15 06:00 [entrez]
PHST- 2011/01/15 06:00 [pubmed]
PHST- 2011/04/22 06:00 [medline]
PHST- 2010/12/27 00:00 [pmc-release]
AID - 10.1155/2011/103917 [doi]
PST - ppublish
SO  - Clin Dev Immunol. 2011;2011:103917. doi: 10.1155/2011/103917. Epub 2010 Dec 27.